Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

What is the purpose of this trial?

People who have smoldering multiple myeloma do not have symptoms but are at risk for progressing to active multiple myeloma. Multiple myeloma is a cancer of the plasma cell, which is an important part of the immune system. People with active multiple myeloma generally require treatment. However, there are currently no approved therapies for smoldering multiple myeloma. The purpose of this study is to determine whether or not an investigational drug is effective and safe in treating people with high risk smoldering myeloma. The name of this investigational drug is elotuzumab. Elotuzumab is a manufactured protein directed against a target found on multiple myeloma cells. Elotuzumab was observed to kill myeloma cells in laboratory studies.

---

Participation Guidelines

Click here for detailed information about who can participate in this trial.

---

Sponsor:

Dates:

March 2012

Last Updated:

Study HIC#:

1110009170

Clinicaltrials.gov ID: Yale2110210